At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 13 enrolled
Drug / intervention
Maraviroc +2 moredrug
Likely dose
Maraviroc 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Pharmacokinetic Study to Assess the Steady State Pharmacokinetic Profile and Short Term Safety of Maraviroc Dosed With Darunavir/Ritonavir All Once Daily, With and Without Nucleoside Analogues, in HIV-1 Infected Subjects
In Brief
A Phase 1 clinical trial evaluating Maraviroc, Truvada, and 1 other intervention for HIV. Completed, enrolled 13 participants across 1 site.
Detailed Summary
This is a phase I, open label, prospective, two phase pharmacokinetic study. Subjects currently attending for HIV care at St. Mary's Hospital, London will be eligible.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2011
Enrollment StartOct 2011
Primary CompletionFeb 2012
Study CompletionMay 2012
TodayJul 2026
First PostedMay 5, 2011
Enrollment StartOct 1, 2011
Primary CompletionFeb 1, 2012
Study CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 15.2 years ago
Interventions
Maravirocdrug
Maraviroc 150 mg daily
Truvadadrug
daily until 10. day then stop
Darunavirdrug
daily until 10. day then stop